


Bismuth Subsalyclate

Cat. No.:	HY-B0550		
CAS No.:	14882-18-9		
Molecular Formula:	C ₇ H ₅ BiO ₄		
Molecular Weight:	362.09		
Target:	PGE synthase		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : < 1 mg/mL (insoluble or slightly soluble)
	H ₂ O : < 0.1 mg/mL (insoluble)

BIOLOGICAL ACTIVITY

Description	Bismuth Subsalyclate is a potent and orally active antacid and anti-diarrheal agent. Bismuth Subsalyclate reduces inflammation/irritation of stomach and intestinal lining through inhibition of prostaglandin synthesis in vivo ^[1] . Bismuth Subsalyclate is widely used for the research of diarrheal disorders, including indigestion, diarrhoea, nausea, et al ^{[1][2]} .
In Vivo	In the gastrointestinal tract, Bismuth Subsalyclate can be converted to salicylic acid and insoluble bismuth salts. Salicylic acid reduces inflammation/irritation of stomach and intestinal lining through inhibition of prostaglandin G/H synthase 1/2 ^[1] . Bismuth Subsalyclate (oral gavage; 100 mg/kg-350 mg/kg) significantly decreases castor oil-induced movement of a charcoal test meal along the small intestine of the mouse and rat and also decreases both the fecal output (dry or wet weight) and the frequency of diarrhea in mice ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Bismuth subsalyclate. Drug.bank

[2]. Alejandra Orona-Ortiz, et al. Mucoadhesive effect of Curcuma longa extract and curcumin decreases the ranitidine effect, but not bismuth subsalyclate on ethanol-induced ulcer model. Sci Rep. 2019 Nov 12;9(1):16622.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA